NextRNA Therapeutics, a biotechnology company unlocking the potential of non-coding RNAs to develop novel and transformative therapeutics, today announced that Dominique Verhelle, Ph.D., Co-Founder, Chief Executive Officer and Chief Scientific Officer, will give a corporate presentation at the 5^th Annual RNA-Targeted Drug Discovery Summit, which will be held December 13 – 15, 2022 in Boston.

Dr. Verhelle’s presentation, which is scheduled to take place on Thursday, December 15 at 1:15 p.m., will explore NextRNA’s proprietary target and drug discovery engine to identify, validate and disrupt disease-relevant interactions between long non-coding RNAs and RNA-binding proteins with small molecules.

About NextRNA Therapeutics 

NextRNA is a biotechnology company unlocking the potential of non-coding RNAs to develop transformative medicines for multiple diseases. The company is leveraging its proprietary technology platform to identify non-coding RNAs and their interacting proteins responsible for disease, and to develop selective small molecules to disrupt these interactions.

For more information, please visit www.nextrnatx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221208005246/en/